Q1 2025 revenue rose 19.49% year-over-year, driven by the Green Cross acquisition, but net profit fell 8.25% due to higher costs and one-time write-downs. Operating cash flow turned negative, and the company expanded its plasma collection and R&D pipeline.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.